The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...